Global Pulmonary Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030

Global Pulmonary Drug Delivery Systems Market by Size, by Type, by Application, by Region, History and Forecast 2019-2030


Summary

Pulmonary drug delivery systems are used to the treatment of various respiratory diseases like asthma and chronic obstructive pulmonary disease (COPD), delivering locally acting drugs directly to their site of action. Advantages of pulmonary drug delivery systems over oral drugs is the excellent capability of absorbing pharmaceuticals, due to the large absorptive surface area of lungs (approximately 70-140 m2 in adult humans having extremely thin absorptive mucosal membrane) and good blood supply.

According to APO Research, The global Pulmonary Drug Delivery Systems market is projected to grow from US$ million in 2024 to US$ million by 2030, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The US & Canada market for Pulmonary Drug Delivery Systems is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Asia-Pacific market for Pulmonary Drug Delivery Systems is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The China market for Pulmonary Drug Delivery Systems is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

Europe market for Pulmonary Drug Delivery Systems is estimated to increase from $ million in 2024 to reach $ million by 2030, at a CAGR of % during the forecast period of 2025 through 2030.

The major global manufacturers of Pulmonary Drug Delivery Systems include 3M, GSK, AstraZeneca, Cipla, Chiesi, Boehringer Ingelheim, Aptar, Novartis and Philips Respironics, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.

This report presents an overview of global market for Pulmonary Drug Delivery Systems, sales, revenue and price. Analyses of the global market trends, with historic market revenue or sales data for 2019 - 2023, estimates for 2024, and projections of CAGR through 2030.

This report researches the key producers of Pulmonary Drug Delivery Systems, also provides the sales of main regions and countries. Of the upcoming market potential for Pulmonary Drug Delivery Systems, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Pulmonary Drug Delivery Systems sales, revenue, market share and industry ranking of main manufacturers, data from 2019 to 2024. Identification of the major stakeholders in the global Pulmonary Drug Delivery Systems market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, sales, revenue, and price, from 2019 to 2030. Evaluation and forecast the market size for Pulmonary Drug Delivery Systems sales, projected growth trends, production technology, application and end-user industry.

Pulmonary Drug Delivery Systems segment by Company

3M
GSK
AstraZeneca
Cipla
Chiesi
Boehringer Ingelheim
Aptar
Novartis
Philips Respironics
Omron Healthcare
PARI
Skyepharma
CareFusion
Shanghai Huarui
Taian Character
Chia Tai Tianqing
Pulmonary Drug Delivery Systems segment by Type

Nebulizers
Dry Powder Inhaler (DPI)
Metered Dose Inhaler (MDI)
Pulmonary Drug Delivery Systems segment by Application

COPD
Asthma
Others
Pulmonary Drug Delivery Systems segment by Region

North America
U.S.
Canada
Europe
Germany
France
U.K.
Italy
Russia

Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.
3. To split the breakdown data by regions, type, manufacturers, and Application.
4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.
5. To identify significant trends, drivers, influence factors in global and regions.
6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Pulmonary Drug Delivery Systems market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Pulmonary Drug Delivery Systems and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market.
5. This report helps stakeholders to gain insights into which regions to target globally.
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Pulmonary Drug Delivery Systems.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Pulmonary Drug Delivery Systems market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2019-2030).
Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Pulmonary Drug Delivery Systems manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Sales of Pulmonary Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 7: Revenue of Pulmonary Drug Delivery Systems in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.
Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Concluding Insights of the report


1 Market Overview
1.1 Product Definition
1.2 Global Pulmonary Drug Delivery Systems Market Size, 2019 VS 2023 VS 2030
1.3 Global Pulmonary Drug Delivery Systems Market Size Estimates and Forecasts (2019-2030)
1.4 Global Pulmonary Drug Delivery Systems Sales Estimates and Forecasts (2019-2030)
1.5 Global Pulmonary Drug Delivery Systems Market Average Price (2019-2030)
1.6 Assumptions and Limitations
1.7 Study Goals and Objectives
2 Global Pulmonary Drug Delivery Systems Market Dynamics
2.1 Pulmonary Drug Delivery Systems Industry Trends
2.2 Pulmonary Drug Delivery Systems Industry Drivers
2.3 Pulmonary Drug Delivery Systems Industry Opportunities and Challenges
2.4 Pulmonary Drug Delivery Systems Industry Restraints
3 Pulmonary Drug Delivery Systems Market by Manufacturers
3.1 Global Pulmonary Drug Delivery Systems Revenue by Manufacturers (2019-2024)
3.2 Global Pulmonary Drug Delivery Systems Sales by Manufacturers (2019-2024)
3.3 Global Pulmonary Drug Delivery Systems Average Sales Price by Manufacturers (2019-2024)
3.4 Global Pulmonary Drug Delivery Systems Industry Manufacturers Ranking, 2022 VS 2023 VS 2024
3.5 Global Pulmonary Drug Delivery Systems Key Manufacturers Manufacturing Sites & Headquarters
3.6 Global Pulmonary Drug Delivery Systems Manufacturers, Product Type & Application
3.7 Global Pulmonary Drug Delivery Systems Manufacturers Commercialization Time
3.8 Market Competitive Analysis
3.8.1 Global Pulmonary Drug Delivery Systems Market CR5 and HHI
3.8.2 Global Top 5 and 10 Pulmonary Drug Delivery Systems Players Market Share by Revenue in 2023
3.8.3 2023 Pulmonary Drug Delivery Systems Tier 1, Tier 2, and Tier 3
4 Pulmonary Drug Delivery Systems Market by Type
4.1 Pulmonary Drug Delivery Systems Type Introduction
4.1.1 Nebulizers
4.1.2 Dry Powder Inhaler (DPI)
4.1.3 Metered Dose Inhaler (MDI)
4.2 Global Pulmonary Drug Delivery Systems Sales by Type
4.2.1 Global Pulmonary Drug Delivery Systems Sales by Type (2019 VS 2023 VS 2030)
4.2.2 Global Pulmonary Drug Delivery Systems Sales by Type (2019-2030)
4.2.3 Global Pulmonary Drug Delivery Systems Sales Market Share by Type (2019-2030)
4.3 Global Pulmonary Drug Delivery Systems Revenue by Type
4.3.1 Global Pulmonary Drug Delivery Systems Revenue by Type (2019 VS 2023 VS 2030)
4.3.2 Global Pulmonary Drug Delivery Systems Revenue by Type (2019-2030)
4.3.3 Global Pulmonary Drug Delivery Systems Revenue Market Share by Type (2019-2030)
5 Pulmonary Drug Delivery Systems Market by Application
5.1 Pulmonary Drug Delivery Systems Application Introduction
5.1.1 COPD
5.1.2 Asthma
5.1.3 Others
5.2 Global Pulmonary Drug Delivery Systems Sales by Application
5.2.1 Global Pulmonary Drug Delivery Systems Sales by Application (2019 VS 2023 VS 2030)
5.2.2 Global Pulmonary Drug Delivery Systems Sales by Application (2019-2030)
5.2.3 Global Pulmonary Drug Delivery Systems Sales Market Share by Application (2019-2030)
5.3 Global Pulmonary Drug Delivery Systems Revenue by Application
5.3.1 Global Pulmonary Drug Delivery Systems Revenue by Application (2019 VS 2023 VS 2030)
5.3.2 Global Pulmonary Drug Delivery Systems Revenue by Application (2019-2030)
5.3.3 Global Pulmonary Drug Delivery Systems Revenue Market Share by Application (2019-2030)
6 Global Pulmonary Drug Delivery Systems Sales by Region
6.1 Global Pulmonary Drug Delivery Systems Sales by Region: 2019 VS 2023 VS 2030
6.2 Global Pulmonary Drug Delivery Systems Sales by Region (2019-2030)
6.2.1 Global Pulmonary Drug Delivery Systems Sales by Region (2019-2024)
6.2.2 Global Pulmonary Drug Delivery Systems Sales Forecasted by Region (2025-2030)
6.3 North America
6.3.1 North America Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.3.2 North America Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
6.3.3 U.S.
6.3.4 Canada
6.4 Europe
6.4.1 Europe Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.4.2 Europe Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
6.4.3 Germany
6.4.4 France
6.4.5 U.K.
6.4.6 Italy
6.4.7 Netherlands
6.5 Asia Pacific
6.5.1 Asia Pacific Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.5.2 Asia Pacific Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
6.5.3 China
6.5.4 Japan
6.5.5 South Korea
6.5.6 Southeast Asia
6.5.7 India
6.5.8 Australia
6.6 LAMEA
6.6.1 LAMEA Pulmonary Drug Delivery Systems Sales Growth Rate by Country: 2019 VS 2023 VS 2030
6.6.2 LAMEA Pulmonary Drug Delivery Systems Sales by Country (2019-2030)
6.6.3 Mexico
6.6.4 Brazil
6.6.5 Turkey
6.6.6 GCC Countries
7 Global Pulmonary Drug Delivery Systems Revenue by Region
7.1 Global Pulmonary Drug Delivery Systems Revenue by Region
7.1.1 Global Pulmonary Drug Delivery Systems Revenue by Region: 2019 VS 2023 VS 2030
7.1.2 Global Pulmonary Drug Delivery Systems Revenue by Region (2019-2024)
7.1.3 Global Pulmonary Drug Delivery Systems Revenue by Region (2025-2030)
7.1.4 Global Pulmonary Drug Delivery Systems Revenue Market Share by Region (2019-2030)
7.2 North America
7.2.1 North America Pulmonary Drug Delivery Systems Revenue (2019-2030)
7.2.2 North America Pulmonary Drug Delivery Systems Revenue Share by Country: 2019 VS 2023 VS 2030
7.3 Europe
7.3.1 Europe Pulmonary Drug Delivery Systems Revenue (2019-2030)
7.3.2 Europe Pulmonary Drug Delivery Systems Revenue Share by Country: 2019 VS 2023 VS 2030
7.4 Asia-Pacific
7.4.1 Asia-Pacific Pulmonary Drug Delivery Systems Revenue (2019-2030)
7.4.2 Asia-Pacific Pulmonary Drug Delivery Systems Revenue Share by Country: 2019 VS 2023 VS 2030
7.5 LAMEA
7.5.1 LAMEA Pulmonary Drug Delivery Systems Revenue (2019-2030)
7.5.2 LAMEA Pulmonary Drug Delivery Systems Revenue Share by Country: 2019 VS 2023 VS 2030
8 Company Profiles
8.1 3M
8.1.1 3M Comapny Information
8.1.2 3M Business Overview
8.1.3 3M Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.1.4 3M Pulmonary Drug Delivery Systems Product Portfolio
8.1.5 3M Recent Developments
8.2 GSK
8.2.1 GSK Comapny Information
8.2.2 GSK Business Overview
8.2.3 GSK Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.2.4 GSK Pulmonary Drug Delivery Systems Product Portfolio
8.2.5 GSK Recent Developments
8.3 AstraZeneca
8.3.1 AstraZeneca Comapny Information
8.3.2 AstraZeneca Business Overview
8.3.3 AstraZeneca Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.3.4 AstraZeneca Pulmonary Drug Delivery Systems Product Portfolio
8.3.5 AstraZeneca Recent Developments
8.4 Cipla
8.4.1 Cipla Comapny Information
8.4.2 Cipla Business Overview
8.4.3 Cipla Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.4.4 Cipla Pulmonary Drug Delivery Systems Product Portfolio
8.4.5 Cipla Recent Developments
8.5 Chiesi
8.5.1 Chiesi Comapny Information
8.5.2 Chiesi Business Overview
8.5.3 Chiesi Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.5.4 Chiesi Pulmonary Drug Delivery Systems Product Portfolio
8.5.5 Chiesi Recent Developments
8.6 Boehringer Ingelheim
8.6.1 Boehringer Ingelheim Comapny Information
8.6.2 Boehringer Ingelheim Business Overview
8.6.3 Boehringer Ingelheim Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.6.4 Boehringer Ingelheim Pulmonary Drug Delivery Systems Product Portfolio
8.6.5 Boehringer Ingelheim Recent Developments
8.7 Aptar
8.7.1 Aptar Comapny Information
8.7.2 Aptar Business Overview
8.7.3 Aptar Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.7.4 Aptar Pulmonary Drug Delivery Systems Product Portfolio
8.7.5 Aptar Recent Developments
8.8 Novartis
8.8.1 Novartis Comapny Information
8.8.2 Novartis Business Overview
8.8.3 Novartis Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.8.4 Novartis Pulmonary Drug Delivery Systems Product Portfolio
8.8.5 Novartis Recent Developments
8.9 Philips Respironics
8.9.1 Philips Respironics Comapny Information
8.9.2 Philips Respironics Business Overview
8.9.3 Philips Respironics Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.9.4 Philips Respironics Pulmonary Drug Delivery Systems Product Portfolio
8.9.5 Philips Respironics Recent Developments
8.10 Omron Healthcare
8.10.1 Omron Healthcare Comapny Information
8.10.2 Omron Healthcare Business Overview
8.10.3 Omron Healthcare Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.10.4 Omron Healthcare Pulmonary Drug Delivery Systems Product Portfolio
8.10.5 Omron Healthcare Recent Developments
8.11 PARI
8.11.1 PARI Comapny Information
8.11.2 PARI Business Overview
8.11.3 PARI Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.11.4 PARI Pulmonary Drug Delivery Systems Product Portfolio
8.11.5 PARI Recent Developments
8.12 Skyepharma
8.12.1 Skyepharma Comapny Information
8.12.2 Skyepharma Business Overview
8.12.3 Skyepharma Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.12.4 Skyepharma Pulmonary Drug Delivery Systems Product Portfolio
8.12.5 Skyepharma Recent Developments
8.13 CareFusion
8.13.1 CareFusion Comapny Information
8.13.2 CareFusion Business Overview
8.13.3 CareFusion Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.13.4 CareFusion Pulmonary Drug Delivery Systems Product Portfolio
8.13.5 CareFusion Recent Developments
8.14 Shanghai Huarui
8.14.1 Shanghai Huarui Comapny Information
8.14.2 Shanghai Huarui Business Overview
8.14.3 Shanghai Huarui Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.14.4 Shanghai Huarui Pulmonary Drug Delivery Systems Product Portfolio
8.14.5 Shanghai Huarui Recent Developments
8.15 Taian Character
8.15.1 Taian Character Comapny Information
8.15.2 Taian Character Business Overview
8.15.3 Taian Character Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.15.4 Taian Character Pulmonary Drug Delivery Systems Product Portfolio
8.15.5 Taian Character Recent Developments
8.16 Chia Tai Tianqing
8.16.1 Chia Tai Tianqing Comapny Information
8.16.2 Chia Tai Tianqing Business Overview
8.16.3 Chia Tai Tianqing Pulmonary Drug Delivery Systems Sales, Price, Revenue and Gross Margin (2019-2024)
8.16.4 Chia Tai Tianqing Pulmonary Drug Delivery Systems Product Portfolio
8.16.5 Chia Tai Tianqing Recent Developments
9 Value Chain and Sales Channels Analysis
9.1 Pulmonary Drug Delivery Systems Value Chain Analysis
9.1.1 Pulmonary Drug Delivery Systems Key Raw Materials
9.1.2 Raw Materials Key Suppliers
9.1.3 Manufacturing Cost Structure
9.1.4 Pulmonary Drug Delivery Systems Production Mode & Process
9.2 Pulmonary Drug Delivery Systems Sales Channels Analysis
9.2.1 Direct Comparison with Distribution Share
9.2.2 Pulmonary Drug Delivery Systems Distributors
9.2.3 Pulmonary Drug Delivery Systems Customers
10 Concluding Insights
11 Appendix
11.1 Reasons for Doing This Study
11.2 Research Methodology
11.3 Research Process
11.4 Authors List of This Report
11.5 Data Source
11.5.1 Secondary Sources
11.5.2 Primary Sources
11.6 Disclaimer

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings